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Traumatic axonal injury (TAI) is an important pathoanatomical subgroup of
traumatic brain injury (TBI) and a major driver of mortality and functional
impairment. Experimental models have provided insights into the effects of
mechanical deformation on the neuronal cytoskeleton and the subsequent
processes that drive axonal injury. There is also increasing recognition that
axonal or white matter loss may progress for years post-injury and represent one
mechanistic framework for progressive neurodegeneration after TBI. Previous
trials of novel therapies have failed to make an impact on clinical outcome, in
both TBI in general and TAI in particular. Recent advances in understanding the
cellular and molecular mechanisms of injury have the potential to translate into
novel therapeutic targets.
TAI is a Common and Severe Subtype of TBI
TBI (see Glossary) is a major public health concern that contributes to one-third of all injury-
related deaths [1] (http://www.cdc.gov/traumaticbraininjury/data). TBI is an emerging research
priority, with large North American and European comparative effectiveness research studies
enrolling several thousands of patients and looking at a broad range of research questions [2–4].
The deﬁnition of TBI is an ‘alteration in brain function, or other evidence of brain pathology,
caused by an external force’ [5]. However, this unitary epidemiological deﬁnition encompasses a
complex disease process with diverse injury subtypes that may overlap (Figure 1). There is an
increasing drive to differentiate these subtypes to allow precision-medicine approaches to
management, where speciﬁc pathobiological processes can be matched to mechanistically
appropriate therapy. Such approaches also need to take account of differences in host
response that arise from coexistent trauma reactions and pre-existing comorbidities. The
temporal evolution of secondary brain injury and associated pathophysiological responses
(Figure 2) that follow the primary brain injury are also important when trying to understand a
TBI. This review examines key molecular mechanisms and potential therapeutic targets in one of
the most common and severe types of TBI, traumatic or diffuse axonal injury [6]. The
terminology regarding axonal injury is in ﬂux but historically the cellular and animal models of
this injury type have been referred to as TAI [6]. This review uses the term TAI to refer to studies
of TBIs where axonal injury is the dominant component, regardless of whether they were
undertaken in human or animals.
Axonal Structure and the Initial Mechanical Injury
Axons can be up to ten thousand times the volume of the parent neuronal cell body and their
elongated structure places them at particular risk of mechanical injury. An axon contains
longitudinal tracks of microtubules arranged in a series of overlapping and highly dynamic
Trends
Multiple therapeutic targets are emer-
ging that offer the potential to reduce
secondary brain injury at a cellular level.
These include cytoskeletal and mem-
brane stabilisation, control of calcium
ﬂux and calpain activation, optimisation
of cellular energetics, and modulation
of the inﬂammatory response.
Wallerian degeneration, as occurs fol-
lowing an axonal injury, is an active,
cell-autonomous death pathway that
involves failure of axonal transport to
deliver key enzymes involved in NAD
biosynthesis.
Chronic microglial activation occurs fol-
lowing traumatic brain injury (TBI) and
may persist for decades afterwards.
This ongoing response has been linked
to long-term neurodegeneration, parti-
cularly of white matter tracts.
Phagoptosis is the process whereby
physiologically stressed but otherwise
viable neurons are phagocytosed by
microglia in response to a range of
eat-me signals induced by tissue injury.
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strands that span the length of the neuron. Microtubules may offer some structural support but
primarily act as polarised tracks for motor proteins. Neuroﬁlaments provide tensile strength
and their radial charges are thought to inﬂuence axonal diameter, while actin ﬁlaments
provide additional membrane stability in the form of a regular repeating ring-like structure that
runs around the circumference of the axon and is held together with spectrin links and adductin
caps [7].
TAI results from high-velocity translational or rotational forces acting on the large, gyrencephalic
human brain, typically due to a motor vehicle accident or fall. Inertial forces shear and stretch
axons to breaking point/primary axotomy or partially damage them, triggering molecular
pathways that result in secondary axotomy/axon degeneration [8]. It is generally accepted that
primary axotomy may be an uncommon component of TAI and would most obviously be found
Glossary
Alzheimer's disease (AD): a
common dementia syndrome that
clinically manifests as cognitive
impairment, especially memory
impairment and behavioural change.
Pathologically it is characterised by
amyloid plaques and neuroﬁbrillary
tangles of tau.
Axonal transport: the cellular
process that moves proteins, lipids,
vesicles, organelles, and other cargos
along the length of an axon. Many
cargos are trafﬁcked bidirectionally
(both away from and towards the
soma) by motor proteins that move
along microtubules or other
cytoskeletal structures found within
the cytoplasm.
Axotomy: a complete physical break
in an axon, often caused by a stretch
injury or laceration. Primary axotomy
occurs at the moment of trauma
while secondary axotomy occurs later
due to secondary injury cascades/
axon degeneration.
Cerebral microdialysis: a technique
for sampling the molecular
components of brain extracellular
ﬂuid by using a dialysate solution to
establish concentration gradients
across a semipermeable membrane.
Involves the insertion of a sampling
microdialysis catheter into a region of
non-eloquent brain parenchyma.
Diffuse axonal injury: a type of
human TBI characterised by a diffuse
distribution of predominantly
secondary axonal injury. A rapid
axonal stretch injury triggers
secondary axonal changes that can
vary in extent and severity. A recent
clinical deﬁnition requires human
brain imaging to show four or more
separate foci of signal abnormality
(http://www.commondataelements.
ninds.nih.gov).
Phagoptosis: the process where
physiologically stressed but otherwise
viable neurons are phagocytosed by
microglia in response to a range of
eat-me signals induced by tissue
injury.
Primary brain injury: the brain injury
that occurs at the moment of impact.
On a macroscopic level, this includes
contusions, lacerations, and
haemorrhages. On a cellular level,
primary axotomy can be included in
this classiﬁcation.
Secondary brain injury: all
deleterious aspects of the brain injury
cascade that occurs following the
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Figure 1. Traumatic Brain Injury Subtypes. There are several different variants of traumatic brain injury, which often
coexist and have signiﬁcant overlap. They can be broadly divided into focal and diffuse injuries, although it is worth noting
that true focal injuries are rare and blast injuries lack a pure neuropathological correlate. The clinical presentation and
prognosis of a traumatic brain injury varies depending on the individual nature of the injury. The inherent variability makes it
challenging to establish the optimal treatment and there is recognition of the value of an individualised approach.
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Figure 2. Cellular and Molecular Activities Resulting in Secondary Brain Injury. Following a traumatic insult to the
brain, an extensive series of various cellular processes is initiated that leads to further neuronal dysfunction and death. This
contributes to the complexity of traumatic brain injury but also provides a variety of therapeutic targets.
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brain. Secondary injury includes
processes that begin seconds after
the injury and may still be evident
decades later. These include
bleeding, energy failure, excitotoxicity,
calcium inﬂux, WD, phagocytosis,
and many others.
Traumatic axonal injury (TAI): the
in vivo or in vitro model equivalent of
diffuse axonal injury. Typically
emulated through the application of a
mechanical stretch insult. The term is
also used to refer to human TBI
cases where there are one to three
separate foci of signal abnormality
(http://www.commondataelements.
ninds.nih.gov).
Traumatic brain injury (TBI): an
alteration in brain function or other
evidence of brain pathology caused
by an external force. This includes
several other subtypes of TBI
including focal and diffuse areas and
patterns of injury.
Wallerian degeneration: a carefully
controlled, active, cell-autonomous,
and evolutionarily conserved death
pathway that is distinct from other
death mechanisms including
apoptosis and necrosis. It involves
the rapid granular fragmentation of an
axon distal to the injury site following
transection, typically occurring after a
latent period of 24–48 h when
modelled in vivo or 4–8 h in vitro
(Box 2).
with a tissue laceration or other direct injury [9]. An elongating stretch of at least 10% that occurs
in 100 ms or less appears to represent a threshold for sublethal axonal injury with secondary
consequences [10]. Some white matter bundles are more vulnerable due to their orientation and
location (for example, the corpus callosum and brainstem) or at interfaces between tissue
compartments of different density such as the grey–white matter junction [11]. Other modiﬁers of
TAI susceptibility include local cellular features, including the stiffness of adjacent tissue,
maximum diversion angle, and internal neuronal cytostructure [12]. Myelination may afford
some degree of protection against TAI, through mechanisms that include metabolic support
by glia, the greater physical robustness of myelinated axons and hence tolerance of greater injury
forces, and better functional recovery [13,14]. An additional driver of variable resilience may be
differences in the site of post-injury ionic ﬂuxes. In myelinated axons the altered ionic gradients
favour nodal and paranodal areas, whereas unmyelinated axons experience more uniform and
widespread injury-induced ionic ﬂuctuations [15].
The classical histological ﬁnding in TAI is of ‘retraction bulbs’, which are thought to develop
following primary axotomy. The term may represent a misnomer, as they are now generally
thought to represent the visualisation of an abnormally accumulated substance, such as the
transmembrane glycoprotein amyloid b precursor protein (APP), due to impaired axonal
transport rather than actual axonal retraction [16]. Primary axotomy is generally considered
relatively rare in human TAI [6], but direct evidence quantifying this is limited. A second major type
of morphological change typically seen in TAI is swelling or varicosities. These are regions of
isolated or multiple axonal swellings (‘beading’) found along the length of an otherwise intact
axon. These have been linked to microtubular dysfunction and fracture [16]. Microtubules have a
viscoelastic nature and are particularly susceptible to breakage because, when rapidly
stretched, they become the stiffest portion of the axon. These breaks lead to microtubular
undulations and impairment of axonal transport with subsequent accumulation of axonal
transport cargos such as bAPP [16,17]. Although similar undulations have occasionally been
demonstrated in sham controls, the consensus is that these appearances provide good
evidence of stretch injury [16,18]. However, not all instances of TAI show bAPP accumulation,
and the true pathophysiological signiﬁcance of axonal swellings is unclear, as is their reliability as
a modiﬁable marker of effective neuroprotection [19]. Hanell et al. provide a review of the different
axonal phenotypes seen in TAI and their potential signiﬁcance [18].
Immunohistochemical analysis for APP accumulation is currently the gold-standard clinical and
experimental technique for assessment of TAI [15]. However, in most instances this is a clinical/
radiological diagnosis and does not require brain tissue. This diagnosis is based on a typical
clinical history of a high-energy TBI coupled with conventional neuroimaging ﬁndings (with X-ray
CT) that show no signiﬁcant focal lesions [15]. MRI has shown marked improvements in
diagnostic sensitivity for TAI in living patients and newer MRI approaches can identify either
biomarkers of the axonal injury itself with diffusion tensor imaging or the microhaemorrhages that
result from injury to the microvessels accompanying white matter using sequences such as
gradient echo and susceptibility-weighted imaging [20,21].
Cytoskeletal Protection
Neuroﬁlaments are the dominant intermediate ﬁlament of axons; they are produced in the
neuronal soma and transported throughout the neurite. Structurally they are obligate hetero-
polymers assembled from a central rod domain surrounded by the neuroﬁlament triplet proteins
(which may be light, medium, or heavy) [22,23]. Neuroﬁlaments may be a key contributor of axon
tensile strength and resilience to mechanical stretch. However, it remains unclear whether they
have additional roles beyond acting as a simple structural protein. Following injury, the axonal
swellings found in TAI develop neuroﬁlament accumulations of all subtypes [24]. Neuroﬁlaments
undergo a process of compaction whereby the interﬁlament spacing is reduced due to side-arm
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phosphorylation or proteolysis and increased density is found within axonal swellings [25]. This
ﬁnding could be due to impaired axonal transport leading to accumulation of cargos, including
neuroﬁlaments. However, the failure of the neuroﬁlament central rod-domain marker RM014,
which is exposed during compaction, to co-accumulate with APP suggests that the compaction
is more complex than a simple transport impairment [23,26,27].
The calcineurin inhibitor FK506 (tacrolimus) is used in humans as an immunosuppressive
agent to reduce the risk of organ rejection. It inhibits phosphatases and hence attenuates the
effects of dephosphorylation-dependent proteases on the neuronal cytoskeleton, including,
neuroﬁlament compaction and spectrin/ankyrin degradation [23,28]. The subsequent reduc-
tion in structural axonal injury and secondary degeneration in experimental models of TAI
implies that this pathway is important in cytoskeletal breakdown, although the effects differ
between axonal subpopulations and are particularly pronounced in unmyelinated axons
[28,29]. A single dose of FK506 in a rat model of lateral ﬂuid-percussion injury has been
shown to reduce loss of dendritic spines and also axonal damage as measured with antibody
labelling of bAPP [29,30]. Pretreatment of cultured primary cortical neuronal axons with
FK506 1 h before an in vitro stretch reduced secondary axotomy [31]. FK506 has also been
suggested as a treatment for post-traumatic epilepsy, which may result from increased
calcineurin activity in the hippocampus [32]. FK506 in combination with hypothermia seems
to protect axons in excess of isolated treatment in a rat lateral-percussion model [33]. Despite
the current clinical use of FK506 as an immunosuppressive agent in humans there are still no
results available for its effects in human TAI.
Microtubule stabilisers including paclitaxel (Taxol) have also been suggested as potential neuro-
protective agents and there is evidence that they may affect the rate of axonal degeneration
[17,34,35]. Unfortunately, paclitaxel has poor blood–brain barrier permeability and serious side
effects in humans, including peripheral neuropathy. Despite this there remains interest in this
therapeutic avenue and Taxol-like agents (taxanes) may as yet prove to be of use [36]. Another
agent thought to act on cytoskeletal proteins is epothilone D. This microtubule-stabilising drug is
brain penetrant and shows evidence of modulating injury-induced axonal sprouting in cortical
neuron cultures following experimentally induced traumatic axotomy [37]. However, despite
emerging evidence for efﬁcacy in spinal cord injury, data directly supporting efﬁcacy in brain injury
remains lacking [37,38].
Spectrin is a key cytoskeletal element whose breakdown leads to the formation of speciﬁc,
quantiﬁable, stable /II spectrin fragments of 145 kDa and 150 kDa (SBP145 and SBP150,
respectively). The SBP145 breakdown product is brain speciﬁc and is found in contusions with
brain necrosis, but an isolated TAI is also sufﬁcient to stimulate its generation. The rise in
breakdown products may occur within 15 min and is reliably demonstrated within 3–24 h
[39,40]. SBPs have been proposed as a potential biomarker of brain injury (Box 1). There
are no examples of direct spectrin stabilisers; prevention of spectrin breakdown by calpain
inhibitors is well documented but the effects of reduced spectrin degeneration on axon survival in
TAI remain largely speculative [41,42].
Ankyrins are a family of adaptor proteins that link the spectrin–actin complex to integral
membrane proteins, a function vital to the maintenance of ion channels within the plasma
membrane. Proteolytic degradation of ankyrin-G following axonal injury may result in misloc-
alisation of sodium channels in nodal regions. It might also encourage instability of the
axolemma through altered binding of neurofascin, a member of the L1 immunoglobulin
superfamily of cell adhesion molecules [43,44]. Hence, direct stabilisation of ankyrin or reduc-
tion of its proteolysis may offer a new therapeutic avenue, if such an intervention could be safely
achieved in humans.
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Cell-Autonomous Axonal Death Pathways
Injury to axons in the central nervous system can lead to death of the whole neuron, although this
may vary by neuronal subtype and with the distance of the injury from the cell body [45,46]. Loss
of the distal axon will also hamper connectivity and the associated reduction in synaptic activity
may inﬂuence overall neuron function even if plastic reorganisation ensues [47]. There are
numerous pathways and pathophysiological processes involved in axon degeneration and
neuronal death (Figure 3, Key Figure). These pathways differ by injury type and also with time
from the injury but may eventually converge. Each process provides the opportunity for
therapeutic intervention, ideally at a point before irreversible structural changes occur.
One mechanism proposed for the loss of axons when axonal transport is impaired is Wallerian-
like degeneration (WLD). This is related to Wallerian degeneration (WD) (Box 2). WLD shows
similarities to WD in molecular regulation and similarly involves granular disintegration of the axon
segment distal to the injury site. Some neuronal cell types, such as the retinal ganglion cell, also
suffer a proximal ‘dying-back’ pathology with soma injury or death after the initial insult [45,48].
Optic nerve stretch modelling has shown that some nerve ﬁbres may also degenerate weeks to
months after the injury. Whether this is a delayed form of WD (for example, following the death or
signiﬁcant impairment of the corresponding soma) or should be considered a separate process
is still being elucidated [49,50].
When subjected to a TBI, WLDsmice (which show delayed Wallerian degeneration) demonstrate
reduced physical evidence of TAI, less evidence of axonal transport disruption (swelling, APP
accumulation, microtubule disruption), and delayed motor and cognitive impairment. These
ﬁndings are consistent with WldS-sensitive degeneration following TAI but this has not been
deﬁnitively conﬁrmed [51]. A recent study of closed head injury (weight drop) in SARM1 knockout
mice has showed evidence of in vivo protection through inhibition of the WLD pathway, with
reduction of behavioural deﬁcits and axonal APP aggregates in the corpus callosum [52].
However, the authors were unable to quantify effects on axonal loss other than indirectly
through phosphorylated neuroﬁlament heavy chain levels [52].
There are no currently available modulators of SARM1. However, as the WD pathway is
increasingly understood other therapeutic targets may emerge within the pathway and offer
Box 1. Molecular Biomarkers in TAI
An effective biomarker of axonal injury would provide a diagnostic tool, a quantitative measure of injury severity, and an
indicator to gauge treatment efﬁcacy. The ideal biomarker would be highly sensitive and speciﬁc for TAI, rapidly reﬂect
changes in injury status, and be easily obtained, such as from a peripheral blood sample. Axon degeneration results in the
generation of cytoskeletal breakdown products and several of these have been explored as potential biomarkers.
Calpains and caspase-3 irreversibly cleave /II spectrin, a neuronal membrane-associated scaffolding protein, into
fragments of various molecular weights. These /II spectrin breakdown products (SBDPs) are found in human cere-
brospinal ﬂuid (CSF) and blood following severe TBI and may predict injury severity and outcome. However, a rise in
SBDPs is not speciﬁc for TAI and may also be found in cerebral ischaemia, neurodegenerative diseases including AD, and
normal ageing [72,118]. Neuroﬁlament light chains are another key cytoskeletal protein with some speciﬁcity for TAI [119].
Axotomy releases phosphorylated neuroﬁlaments into the blood and CSF that may correlate with injury severity [120]. A
third element to be explored as a biomarker is glial ﬁbrillary acidic protein (GFAP) and its breakdown products. GFAP is a
brain-speciﬁc intermediate ﬁlament that is prevalent in astrocytes and correlates with intracranial injury [121]. Other
cytoskeletal products that are being investigated include the microtubule-stabilising protein tau and microtubule-
associated protein 2 (MAP2) [119]. Many non-cytoskeletal molecules are also being investigated as potential biomarkers
in TBI; these include S100-b (a 21-kDa calcium-binding protein), neuron-speciﬁc enolase (a 78-kDa g-homodimer
glycolytic enzyme isomer), and the neuron-speciﬁc protein ubiquitin C-terminal hydrolase (UCH-L1). An alternative
approach to biomarker detection is to characterise functional responses to injury. Cerebral microdialysis in both
experimental models and human TBI captures the generation of a wide range of pro- and anti-inﬂammatory cytokines
and chemokines in response to brain injury. However, the complex pattern of production with temporal variation,
covariance, and multiple interactions makes their interpretation and use as biomarkers challenging [101,122]. Despite
active research, biomarkers that are speciﬁc for axonal injury, as opposed to nonspeciﬁc markers of brain injury, are
lacking, and an ideal marker remains to be identiﬁed.
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new treatment opportunities. One example is P7C3 and related compounds; this aminopropyl
carbaxole discovered using an unbiased in vivo screening approach for neurodegenerative
disease modiﬁers seems to be proneurogenic and antiapoptotic [53]. P7C3 is thought to bind to
nicotinamide phosphoribosyltransferase (Nampt), possibly enhancing its activity [54]. Nampt is a
rate-limiting enzyme important in WD that converts nicotinamide to NMN and subsequently
Key Figure






































Figure 3. Mechanical stretch leads to undulation of the axon and activation of various injury pathways. Direct membrane mechanoporation and opening of exchange
channels leads to calcium inﬂux. This activates calpains, which degrade structural proteins. Proinﬂammatory cytokines have broad effects including initiation of caspase-
mediated proteolysis and microglia recruitment. Calcium inﬂux also triggers generation of the mPTP, with subsequent solute inﬂux and mitochondrial dysfunction/death.
Reactive oxygen species are generated and result in oxidative damage. Neuroﬁlaments compact and aberrant proteins including TDP43 and amyloid ﬁbrils accumulate.
Microtubules are fractured; this leads to impairment of axonal transport with failure to deliver nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) and
subsequent Wallerian degeneration. Eat-me signals including phosphatidylserine are externalised and may initiate phagoptosis of stressed neurons by microglia. Note
that although NMDA channels are shown on the axon for simplicity, most are localised on dendrites and dendritic spines and axonally based channels are in a minority.
Abbreviations: TDP43, transactive response DNA-binding protein 43 kDa (a nuclear-pore transport protein, the cytoplasmic mislocalisation and aggregation of which is
associated with chronic traumatic encephalopathy, frontotemporal dementia and amyotrophic lateral sclerosis); NMDA receptor, a glutamate receptor/ion channel that is
a channel for calcium ion ﬂux. mPTP, mitochondrial permeability pore (when induced in mitochondria by tissue injury this allows solute inﬂux, leading to mitochondrial
swelling and death).
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NAD. Further in vivo work in models of blast injury and TBI have shown that P7C3 can provide
neuroprotection and/or preservation of function [55,56]. However, there are still questions about
the exact mechanism of P7C3 action and it remains unclear how the apparent neuroprotection
provided by Nampt activation can be reconciled with the ﬁnding that the Nampt inhibitor FK866
has also been shown to delay WD [57].
Mechanotransduction and Calcium Permeability
When a central nervous system axon is stretched there is an acute increase in intracellular
calcium primarily derived from intracellular stores. This is followed by a more gradual and long-
lasting dysregulation of intracellular calcium metabolism [31,58]. Although as yet unproved, it has
been suggested that physical forces may lead to ‘mechanoporation’, a term variably used to
refer to either direct or secondary opening of the axolemma, leading to intracellular ﬂuxes of
calcium [58–61]. Calcium has established roles in many forms of cell death, including the
apoptotic death pathway and WD, and is therefore a potential therapeutic target in TAI.
Increases in intracellular cytoplasmic calcium, such as might occur with an inﬂammatory
response to a traumatic injury, disruption of energy metabolism, or damage to the cell mem-
brane, can trigger a pathogenic cascade culminating in cell death [31]. A focal increase in
calcium concentration in an axon precedes, and can result in, the development of axonal
spheroids [62]. Conversely, spheroid formation can be prevented by the blockage of NCX1, N-,
or L-type voltage-gated calcium channels, possibly by preventing a threshold level of axolemmal
calcium from being reached [62]. While the beneﬁt of preventing such ultrastructural changes
remains unproved, it is evident that an unchecked increase in intracellular calcium levels can
trigger secondary axotomy. The mechanism by which this is likely to occur includes active
destruction of the cytoskeleton mediated by calcium-dependent calpains, caspases, cysteine
proteases, and phosphatases in response to cytosolic accumulation of calcium [63]. Addition-
ally, mitochondrial sequestration of calcium can result in energetic dysfunction, generation of
reactive oxygen species, and subsequent oxidative damage [23].
Attempts to use agents such as Kollidon VA64 to reseal microdefects in the plasma membrane
following injury aim to guard against mechanoporation-related calcium damage. Initial in vivo
results with this agent in rodent models of TBI have been encouraging [64]. Alternative
membrane-resealing agents include poloxamer 188. This non-ionic surfactant has been
shown to inhibit apoptosis and necrosis in vitro after a stretch injury and exhibits neuro-
protective effects following TBI in animal models but has not been tested in humans. The exact
mechanisms of action of this agent are debated but may partially involve inhibition of p38
mitogen-activated protein kinase (p38-MAPK) activation or cathepsin B- and tBid-mediated
mitochondrial cell death triggering [65]. Other ‘membrane-sealing’ compounds are currently
undergoing preclinical testing, including PEG-PDLLA micelle treatment, polyethylene glycol,
and tripartite motif (TRIM) proteins like Mitsugumin 53 [66–68]. A barrier to clinical translation in
Box 2. Molecular Control of WD
The full molecular mechanism of WD is still being determined. One evolving model suggests that a key step in WD is failure
to deliver the enzyme nicotinamide mononucleotide (NMN) adenylyltransferase 2 (NMNAT2), an essential survival factor,
from the neuronal soma to the distal axon. Loss of NMNAT2 beyond the site of injury due to either interrupted transport or
transection of the axon leads to a reduction in the ubiquitous coenzyme NAD and an increase in its precursor NMN. Mice
expressing a mutant slow WD protein (WLDs) that provides a more stable form of NMNAT activity in the axonal periphery
are less dependent on ongoing transport of NMNAT2 from the neuronal soma and exhibit markedly slower Wallerian-like
degeneration [123]. It has been proposed that it is NMN that may ultimately lead to the triggering of WD [57]. Other
possibilities include a direct effect of NAD depletion or some combination of the two [124]. A crucial downstream
regulator of this intrinsic axonal self-destruct pathway is the sterile alpha and TIR motif-containing 1 (SARM1) protein.
SARM1 mediates rapid fragmentation of severed axons and when this factor is knocked out axons show a robust
delayed degeneration phenotype that is comparable with WLDs [80,125]. The mechanism by which SARM1 regulates
axon degeneration is still being elucidated, but recent data indicate that SARM1 either acts downstream on the NMNAT
pathway or regulates a separate branch that converges at a downstream point [124,126].
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this context is the rapidity of calcium rise following injury, which makes direct prevention of early
calcium entry problematic.
Calpains as a Convergence Point in Axonal Degeneration
Excitotoxicity has a long history of being implicated as a secondary brain injury mechanism
contributing to neuronal death following trauma. Excitotoxic cell death is intimately linked to
downstream calcium ion inﬂux modulation and dysregulation, which is mediated in part by
calpains [69]. Extracellular glutamate levels have been shown to be elevated in both experimental
and human TBI, but the failure of glutamate antagonists in clinical trials has resulted in interest
shifting to downstream targets, including calpains [70]. Calpains are calcium-dependent, non-
lysosomal cysteine proteases. Their baseline activity is low and in normal physiological con-
ditions they are predominantly involved in cell signalling and plasticity [42]. In response to axonal
injury and associated calcium shifts, calpains move from the cytosol to the plasma membrane,
where sustained activation causes widespread proteolysis. Several membrane, adhesion, and
structural cytoskeletal proteins are targeted by calpains, including the key cytoskeletal protein
spectrin. Calpains have been strongly implicated in the later stages of WD in both the peripheral
and central nervous system [69]. Their ability to degranulate the distal segment of injured axons
may be partly due to in vivo proteolysis of neuroﬁlaments, although the exact steps in such a
mechanism have not been fully described [71]. Calpain activity within motor nerve terminals at
the neuromuscular presynaptic junction may also cause denervation, although whether this
precedes or follows axonal degeneration is unclear [71]. While calpain inhibition has shown
robust morphological protection this has not extended to electrophysiological function ex vivo –
a failing that may limit human translation [71]. Continued interest in this pathway is driven by the
belief that widespread calpain activation may be an early mediator of additional secondary brain
injury in TAI and by the fact that calpain-induced spectrin breakdown provides speciﬁc
molecular biomarkers of the process [72] (Box 1). Subaxolemmal calcium-induced calpain-
mediated proteolysis may contribute to the axolemmal permeability observed in TAI. Calpains
may also cause long-term deﬁciencies in axonal transport and plasticity leading to persistent
dysfunction and poor clinical recovery. Recognition of these potential roles in ongoing degen-
eration has focussed efforts on inhibition of calpain as a therapeutic strategy, primarily aimed at
affording cytoskeletal protection. This may be achieved either directly with calpain/protease
inhibitors or indirectly by reducing intracellular free calcium [42]. Numerous compounds that
target excitotoxic calcium-, calpain-, or caspase-related mechanisms have been investigated
in the context of TAI and TBI. A range of these has progressed to human trials, many based
around targeting glutaminergic excitotoxicity mediated by the NMDA receptor. Examples
include magnesium sulfate [73], selfotel (CGS 19755) [74], dexanbinol [75], and amantadine
[76]. Unfortunately, none of these interventions have shown beneﬁt in clinical TBI. Several
calpain- and caspase-based agents have been trialled in rodent models with mixed success
but these have not progressed to human trials. Although there remains hope that some of these
therapies may ﬁnd use in clinical practice, they share common inherent limitations, including
unwanted modulation of otherwise beneﬁcial cell activities, and logistic difﬁculties around the
need for early drug administration.
Mitochondria and Energetics in TAI
Axonal stress is associated with reduced mitochondrial movement, disruption of cristae, and
swelling, coalescence, or fragmentation of mitochondria [77]. Axons are sensitive to energy
depletion and utilise ATP to sustain membrane potentials and ionic gradients, prevent abnormal
calcium inﬂux, and sustain transport of cargos (including mitochondria) within the axon. After
primary axotomy, mitochondrial respiration and glycolysis fall [78,79], resulting in a decline in
ATP levels that can contribute to irreversible axonal damage [79,80], although a recent report
indicates that loss of mitochondrial membrane potential can be quite a late event [81]. Modula-
tion of energetic failure remains a potential therapeutic target in TAI, either directly to ameliorate
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axonal energy failure or to address mitochondria-related injury. There are several ways in which
mitochondrial dysfunction may contribute to axonal pathology. When subjected to injury, axons
are sites of reactive oxygen species production, energy failure, and mitochondrial permeability
pore (mPTP) generation [82]. The mPTP is an inner membrane protein that is induced in
response to increased calcium matrix concentration and allows movement of small molecules
(<1.5 kDa) in or out of the mitochondria, a process that may lead to swelling and death [83,84].
The view that the mPTP participates in axonal degeneration has led to its study as a potential
therapeutic target in TAI. Cyclosporin A is a commonly used immunotherapeutic drug that binds
and inhibits cyclophilin D, a protein complex purported to be involved in the opening of the mPTP
[85]. Cyclophilin D knockout mice show decreased numbers of distal, but not proximal, axonal
bulbs and varicosities in a ﬂuid-percussion mouse model of TAI [18]. Results with cyclosporin A
administration in TAI models are mixed. Pretreatment with cyclosporin A failed to reduce axonal
swelling in primary neuronal cultures exposed to reactive oxygen species [62]. However,
cyclosporin A does attenuate cytoskeletal changes and axon degeneration after a mild axon
stretch injury, while intrathecal administration reduced delayed axotomy in a rat acceleration
model [86]. Human Phase II trials of cyclosporin are currently underway. A similar approach uses
the cyclosporin analogue NIM811, which also binds to cyclophilin D and prevents the formation
of the mPTP [87]. NIM811 reduces calpain-mediated spectrin degradation, neuronal degenera-
tion, and cognitive deﬁcits when administered up to 12 h after a traumatic injury [88,89]. FK506
(tacrolimus) may also have a role in modulating cellular energetics, since it inhibits calcineurin and
hence reduces translocation of BAD to BCL-X in mitochondria, with reduction of mPTP opening
[15].
Attempts to improve mitochondrial energetics have included the use of N-acetyl cysteine [90]
which has shown potential symptomatic beneﬁt when used in mild military blast injury [91].
Exposure to low-level laser light or 670-nm light provides a novel non-pharmacological approach
to improve mitochondrial energetics through alteration of redox state and transcription factor
expression while inducing modest increases in nitric oxide and reactive oxygen species. This
technique has the potential for human applications and, in addition to isolated case studies, has
shown beneﬁt in animal models [92,93]. There may be scope to combine this technique with
systemic administration of methylene blue, a compound that interacts with numerous targets,
acts as a redox cycler, and upregulates mitochondrial energetics [94]. Methylene blue may also
promote autophagy, reduce brain oedema, and inhibit microglial activation [95,96].
Another mitochondrial target identiﬁed with in vitro stretch modelling is cardiolipin peroxidation.
The compound XJB 5131 has been shown to reduce lipid oxidation and caspase activation in a
rat cortical contusion model, with subsequent improvement in both lesion size and functional
measures [97]. Further research is still required to characterise the compound before its use
beyond rodent models can be considered.
Creatine is an endogenous amino acid, administration of which can increase stores of the high-
energy metabolite phosphocreatine. Creatine may directly act on central nervous system axons
and modify response to brain injury by inhibiting calcium-induced activation of the mPTP,
maintaining ATP levels, preserving normal mitochondrial membrane potentials, and reducing
intramitochondrial calcium levels [98]. A randomised pilot study in children with severe TBI was
encouraging, with some prevention of post-traumatic symptoms and improvement in several
parameters including length of intensive care unit stay and cognition [99].
Inﬂammation and Microglial Phagocytosis and Phagoptosis
TAI triggers a complex cascade of inﬂammatory response with release of cytokines, chemokines
and growth factors by microglia, astrocytes, and neurons [100]. Many cytokines and chemo-
kines are capable of inducing mixed pro- and anti-inﬂammatory effects under speciﬁc
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conditions. This duality of function makes it difﬁcult to disentangle their beneﬁcial and detrimental
effects [101]. Thus far, despite often promising preclinical results, agents that modulate the
inﬂammatory response have failed to deliver clinical beneﬁt in human TBI. Prominent examples
include corticosteroids and anti-tumour necrosis factor (TNF) therapy [75,102]. Blocking of the
‘proinﬂammatory’ interleukin (IL)-1 receptor remains a therapeutic target and is the subject of
ongoing investigation in the form of a Phase II clinical trial that is examining IL-1ra [103].
Purinergic signalling through cognate transmembrane receptors represents a core part of the
neuroinﬂammatory response. Adenosine signals via P1 receptors while ADP and ATP activate
P2 receptors. Stretched cells, including astrocytes, can release their intracellular stores of ATP,
which activates ionotropic P2X7 receptors localised to astrocytic end feet and colocated with
aquaporin 4 expression. P2X7 activation leads to IL-1b-mediated exacerbation of local neuro-
inﬂammation, reactive gliosis, and cytotoxic oedema. It also results in membrane poration and
increased tissue damage as a result of enhanced calcium inﬂux [104,105]. Brilliant Blue G (BBG)
directly antagonises P2X7 and might downregulate this damaging response up to 4 h post-injury
[106]. The compound is nontoxic and has shown promise in attenuating optic nerve crush
injuries and rodent TBI models, although the effects have been mild and not all results have been
reproducible [106,107].
Following TBI there is rapid and widespread activation of microglia. Temporally, the numbers of
microglia appear to follow a multiphasic pattern with early and late peaks [108]. Beyond the
acute inﬂammatory phase, chronic microglial activation is triggered that can persist for months or
years. This has been shown in murine models 1 year following experimental brain injury and in
human subjects with the PET ligand [11C](R)PK11195 [109,110]. Post-mortem examination of
the brains of TBI survivors who die of other causes at varying intervals after injury demonstrates
ongoing activation years and decades after the original insult, in association with regions of
substantial white matter volume loss [49]. This has been proposed as a potential mechanism
linking TBI and late neurodegeneration, including Alzheimer's disease (AD) (Box 3). Similarly to
the cytokine/chemokine response, microglia can be polarised within a spectrum that includes
Box 3. Links between TAI and Neurodegeneration
TBI is a major environmental risk factor for the development of AD [127] and chronic traumatic encephalopathy (CTE)
[128] and has been implicated in frontotemporal dementia and motor neuron disease (MND)/amyotrophic lateral sclerosis
(ALS), albeit inconsistently [129,130]. There are various potentially signiﬁcant mechanistic links between TAI and AD,
mostly converging around amyloid b and tau generation. TAI is thought to directly disrupt microtubule dynamics creating
an impairment of axonal transport that subsequently leads to the characteristic histological ﬁnding of accumulations of
APP cargo [16]. APP can undergo cleavage into amyloid b peptides, a key feature of AD, that aggregate into amyloid
plaques. Some of these amyloid b species are directly neurotoxic, with oligomers including Ab42 being particularly
implicated [131]. Cortical-impact modelling has shown that injury can induce aggregation and oligomerisation of amyloid
in a triple-transgenic AD mouse model [132]. Casualties of severe TBI may have increased brain amyloid levels, as
detected by PET or histology several years following injury, that could correlate with outcome [19,133,134]. In contrast to
the PET ﬁndings, reductions in CSF levels of Ab42 have been noted following TBI. This decline may be due to a temporary
reduction in neuronal activity due to dysfunction, leakage across an opened blood–brain barrier, or deposition into
insoluble plaques [135]. Tau is a microtubule-associated protein that, along with amyloid b, is considered by many to be a
primary component of AD pathology. In AD, tau is seen to form hyperphosphorylated aggregates called neuroﬁbrillary
tangles. Increased tau levels in the extracellular space following severe TAI correlate with reduced amyloid b levels and
adverse outcomes [136]. Recently, acute neuronal production of cis-phosphorylated tau (cPT) was found following TBI in
mice and in hypoxic/serum-starved neurons in vitro [137]. It has been proposed that cPT is pathogenic. Pretreatment or
post-injury treatment of mice with a cPT antibody blocked the increase in cPT and restored a range of structural and
functional sequelae including risk-taking behavior and brain atrophy [137,138]. This provides an example of a novel
potential biomarker and therapy that has shared implications for TAI and sporadic neurodegenerative disease. CTE is an
increasingly recognised neurodegenerative condition that occurs following repeated TBI, often in the context of contact
sports or military blast. The pathological mechanism is still being elucidated but the neuropathological hallmarks of
perivascular tau accumulation and mislocalised cytoplasmic aggregation of transactive response DNA-binding protein 43
kDa (TDP43) may suggest common links and therapeutic avenues with sporadic neurodegenerative diseases like
frontotemporal lobar degeneration (FTLD) and MND/ALS [139].
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classical/proinﬂammatory and alternative/reparative phenotypes with different mechanistic
impacts [111,112]. Understanding this balance and the complexities of mixed phenotypes
so that they can be modiﬁed in a beneﬁcial way is an important challenge in TAI research.
Phagocytosis and debris clearance is required for maintenance of tissue homeostasis, regen-
eration, and plasticity but may be detrimental when occurring in excess [113]. Severing of
neurites or traumatic injury causes translocation of phosphatidylserine residues from the inner
plasma membrane to the cell exterior. This is one of several ‘eat-me’ signals in injured neurons,
recognised by activated microglia, and can trigger phagocytosis of the injured neuron [114].
More recently, the concept of phagoptosis has emerged. Molecules that are expressed by
stressed neurons and known to directly trigger the phagoptotic response include phosphati-
dylserine and desialylated glycoproteins. Alternatively, opsonins and receptors including MertK,
MFG-E8, galectin-3, protein S, and GAS6 can act as intermediaries [114,115]. Counter-regula-
tory ‘don’t-eat-me’ signals also exist and include neuraminidase [114,116]. Although this
description of microglia-mediated injury is plausible, we do not know yet whether such phag-
optosis signals are displayed in response to TAI. If this injury mechanism is conﬁrmed, modula-
tion of phagoptosis could potentially allow rescue of these partially but not irreversibly injured
neurons. Whether these cells could then recover and functionally reintegrate in a beneﬁcial
manner would be an important subsequent question.
Concluding Remarks: Mechanistic Understanding May Translate to
Therapies
Despite increasing interest in and research into TAI, there has so far been a notable lack of
translation into efﬁcacious patient therapies [70]. The extensive range of in vitro and in vivo
models that exists to examine various aspects of TAI has contributed to substantial advances in
mechanistic knowledge of axonal injury and death pathways [117]. However, because
of inherent limitations of model systems it is critically important to explore and compare
pathophysiology in human TBI, for example through cerebral microdialysis and imaging
technologies, to be certain that results obtained in TBI models are applicable in clinical settings.
Crucial questions remain but the hope is that increased knowledge gained from an improved
mechanistic understanding of injuries will translate into effective therapies and improved clinical
outcomes.
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